/stocks — the workspaceLOADING
All XBIT SEC filings, by type → · Earnings date & implied move · Search inside filings
XBiotech Inc. (XBIT) is a pharmaceutical preparations company. Fundamentals from SEC filings; prices are end-of-day.
What’s behind XBIT’s latest move — the size, how unusual the volume is, and the catalyst on the tape, explained and cited to the source.
End-of-day bars · delayed, not real-time · data: Databento · studies computed in your browser from these barsCharting by TradingView Lightweight Charts™
No sensitivity grid: free cash flow is not positive, so the DCF gives no value at any growth or discount rate.
Estimates, not targets. The DCF treats free cash flow as cash flow to equity and divides by shares (the common retail shortcut — it skips net debt and a full WACC), so it’s a sanity-check, not a valuation opinion. All inputs are from XBIT’s SEC filings; change any assumption above and the numbers update live. Educational only — not investment advice.
A plain-English read on XBIT plus an auto-SWOT — built from XBIT's SEC filings and market data, every point cited, nothing invented. Educational, not investment advice.
Four AI analysts — a bull, a bear, a risk manager, and a PM — debate XBIT using only the SEC-filing and market facts below. Every point cites its evidence; nothing is invented. This is educational research, not investment advice.
Educational only — not financial advice. Data from SEC EDGAR public filings; no live market data is shown. Figures reflect the company's own reported XBRL facts and may lag.
XBRL company facts, SEC EDGAR. TTM = last four reported quarters. Valuation ratios arrive with a price source — we don't fake quotes.
↓ Download the fiscal-year statement table: XLSX · CSV · revenue, income, EPS, cash flow, balance sheet · from SEC XBRL, dated
As filed. We do not recategorize line items. Each chart plots one XBRL concept exactly as XBIT tagged it: revenue us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax, net income us-gaap:NetIncomeLoss, EPS us-gaap:EarningsPerShareBasicAndDiluted, period by period; a period the company did not tag on its own is left out, not estimated. A figure that disagrees with the filing is a bug in our extraction, not a policy, and we fix it: report a mismatch.
Projected from XBIT's own SEC 8-K filing history — the year-over-year reporting pattern (about 47% land the exact day, about 91% within a week, measured across 4,713 past reports). No analyst estimates and nothing invented, and every confirmed date links to the source it came from, so you can check it yourself. It upgrades the momentXBIT files or announces.
Earnings dates are the company's 8-K Item 2.02 filings (SEC). Reactions from Databento EOD.
No tracked institution reported a position in XBIT in the latest 13F round.
No lawmaker has disclosed a trade in XBIT under the STOCK Act.
None of the 5 estimators could run on XBIT's filings.
One estimator is a point estimate, not a range, so no band and no valuation label are published for XBIT. Below is everything that was checked, so the refusal can be read rather than taken on trust.
Nothing produced a value.
No fiscal year of price history was on record; the historical multiples need 5. No sector peer set is priced for XBIT, so sector medians could not fill the gaps.
Every refusal recorded for XBIT → · How often we decline, and why →
No open-market Form 4 buys or sells reported for XBIT in the last ~6 months.
2 of the 2 checks that ran found nothing new for XBIT. 2 could not run.
Each event check looks back 30 days from the date its own source was stored, read or generated, never from the date this page was built. A check that finds nothing is a measurement of that window, not a forecast, and a check that cannot be dated does not make the claim at all.
Head office: Austin, Texas, United States · the company’s charter and its head office are in different countries.
Source: the cover page of XBiotech Inc.’s 10-Q filed 2026-08-13, on EDGAR. Filings checked 2026-10-23. Incorporation is where the company’s charter was filed. It is not where the business operates or earns, which no filing cover states. How this works